<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04999527</url>
  </required_header>
  <id_info>
    <org_study_id>DISC-0974-101</org_study_id>
    <nct_id>NCT04999527</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DISC-0974 in Healthy Subjects Following Dose-Escalating Single Intravenous Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Disc Medicine, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Disc Medicine, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK)&#xD;
      and Pharmacodynamics (PD) of DISC-0974 in adult healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled participants in this study will receive a single dose of DISC-0974 or a placebo.&#xD;
      Samples will be collected to measure how DISC-0974 is processed by the body and how the body&#xD;
      responds when exposed to DISC-0974. Participants will receive a single study drug dose on Day&#xD;
      1; and follow-up for 10 weeks (71 days). If an undetectable DISC-0974 blood concentration is&#xD;
      observed, the duration of follow-up will be shortened to 7 days thereafter, as feasible.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2021</start_date>
  <completion_date type="Anticipated">February 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 16, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 71 days of monitoring</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal laboratory test results</measure>
    <time_frame>Up to 71 days of monitoring</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent clinically abnormal electrocardiogram (ECG)</measure>
    <time_frame>Up to 71 days of monitoring</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent clinically abnormal physical exam</measure>
    <time_frame>Up to 71 days of monitoring</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma maximum measured drug concentration (Cmax)</measure>
    <time_frame>Up to 71 days of testing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration (Tmax)</measure>
    <time_frame>Up to 71 days of testing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>Up to 71 days of testing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life (T½)</measure>
    <time_frame>Up to 71 days of testing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteer: Single Ascending Dose of DISC-0974</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Intravenous (IV) ascending dose in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteer: Single Ascending Dose of Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Intravenous (IV) ascending dose in healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DISC-0974</intervention_name>
    <description>DISC-0974 is administered (IV infusion) as a single dose</description>
    <arm_group_label>Healthy Volunteer: Single Ascending Dose of DISC-0974</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is administered (IV infusion) as a single dose</description>
    <arm_group_label>Healthy Volunteer: Single Ascending Dose of Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female (HV only) adults aged 18 to 65 years, inclusive at the time of consent.&#xD;
&#xD;
          -  Body weight ≥50 kg and body mass index (BMI) between 18 and 33, inclusive, at&#xD;
             Screening.&#xD;
&#xD;
          -  Systolic blood pressure ≤140 mmHg and diastolic blood pressure ≤90 at Screening.&#xD;
&#xD;
          -  No clinically significant abnormalities as determined by medical history, by results&#xD;
             of physical examination, vital signs, ECG and lab tests at Screening.&#xD;
&#xD;
          -  QTcF &lt;450 msec at Screening.&#xD;
&#xD;
          -  Estimated glomerular filtration rate &gt;60 mL/min/1.73m2 based on the 4 parameter MDRD&#xD;
             (Modification of Diet in Renal Disease) equation at Screening&#xD;
&#xD;
          -  TSAT ≤30% at Screening, as determined in a fasting morning blood sample (06:00 to&#xD;
             11:00 hours).&#xD;
&#xD;
          -  Hematologic parameters (red blood cell count [RBC], hemoglobin, hematocrit, platelet&#xD;
             count, mean corpuscular volume, mean corpuscular hemoglobin concentration), serum&#xD;
             iron, and TIBC within normal range and serum ferritin (within normal range and ≥30&#xD;
             ng/mL) at Screening.&#xD;
&#xD;
          -  If a male with female sexual partner(s) of childbearing potential, must agree to use&#xD;
             acceptable methods of birth control during the study and through the End of Study&#xD;
             (EOS) visit&#xD;
&#xD;
          -  If female, postmenopausal, as defined with at least 12 months natural, spontaneous&#xD;
             amenorrhea, or at least 6 weeks following surgical menopause&#xD;
&#xD;
          -  Able to understand and provide written informed consent and comply with protocol&#xD;
             requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of anemia or hematologic disorder within 1 year of Screening&#xD;
&#xD;
          -  History of splenectomy&#xD;
&#xD;
          -  Diagnosis or first-degree relative with a diagnosis of hemochromatosis&#xD;
&#xD;
          -  History of diabetes, cardiovascular, hepatic, renal, or malabsorptive disease&#xD;
&#xD;
          -  Vegan or iron-deficient diet within 3 months of Screening&#xD;
&#xD;
          -  Blood transfusion within 1 year of Screening&#xD;
&#xD;
          -  Whole blood donation within 6 months of Screening or plasma donation within 30 days of&#xD;
             Screening.&#xD;
&#xD;
          -  A history of alcohol or illicit drug use disorder within 3 years of Screening, as&#xD;
             assessed by the Investigator&#xD;
&#xD;
          -  Use of any tobacco- and/or nicotine-containing containing products, including&#xD;
             e-cigarettes, vaping products, and nicotine replacement products, within 3 months of&#xD;
             Screening&#xD;
&#xD;
          -  Use of multivitamin or iron supplements within 30 days prior to Screening&#xD;
&#xD;
          -  ALT or aspartate aminotransferase (AST) level above the normal range at Screening&#xD;
&#xD;
          -  Positive urine pregnancy test at Screening or Baseline (Day -1).&#xD;
&#xD;
          -  Positive serologic test for Hepatitis B surface antigen, Hepatitis C antibody, or&#xD;
             human immunodeficiency virus (HIV) at Screening.&#xD;
&#xD;
          -  Positive urine screen for drugs of abuse or alcohol test on admission to the study&#xD;
             center&#xD;
&#xD;
          -  Use of any systemic prescription medication within 14 days of Screening, non-iron&#xD;
             containing dietary supplements, or non-prescription drugs within 7 days of dosing.&#xD;
&#xD;
          -  History of a major surgical procedure within 60 days of Screening or planned surgical&#xD;
             procedure within 90 days of dosing.&#xD;
&#xD;
          -  A history or known allergic reaction to any investigational product excipients or&#xD;
             history of anaphylaxis to any food or drug.&#xD;
&#xD;
          -  History or presence or any illness that, in the opinion of the Investigator, would&#xD;
             interfere with the ability to provide informed consent or comply with study&#xD;
             instructions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Savage, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Disc Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Wood</last_name>
      <phone>210-635-1515</phone>
      <email>audrey.wood@worldwide.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.discmedicine.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

